fluorouracil has been researched along with Coronary Artery Vasospasm in 67 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy." | 8.12 | The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. ( Blaszkowsky, LS; Clark, JR; Clark, JW; Drobni, ZD; Gilman, HK; Gongora, CA; Hartmann, S; Jones-O'Connor, M; Lei, M; Lou, UY; Mahmood, A; Mosarla, R; Murphy, SP; Neilan, TG; Nipp, R; Quinaglia, T; Tavares, E; Weekes, CD; Zafar, A, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 8.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 7.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 7.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "A case of 5-fluorouracil-induced cardiotoxicity, possibly due to coronary artery spasm, and mimicking acute anterolateral myocardial infarction is presented and discussed." | 7.71 | 5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. ( Campbell, NP; McGlinchey, PG; Webb, ST, 2001) |
| "Capecitabine has been shown to be much less cardiotoxic compared to 5-FU, with only a handful of cases reporting cardiotoxicity with capecitabine." | 5.43 | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016) |
| "Capecitabine is an orally available chemotherapeutic agent that is converted to 5-fluorouracil (5-FU) after absorbtion." | 5.38 | Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible. ( Celiker, E; Eren, M; Güvenç, TS; Ilhan, E; Ozcan, KS, 2012) |
| "Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors." | 5.38 | Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012) |
| "Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil." | 5.35 | Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008) |
| "Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal." | 5.35 | Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008) |
| "Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy." | 4.12 | The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. ( Blaszkowsky, LS; Clark, JR; Clark, JW; Drobni, ZD; Gilman, HK; Gongora, CA; Hartmann, S; Jones-O'Connor, M; Lei, M; Lou, UY; Mahmood, A; Mosarla, R; Murphy, SP; Neilan, TG; Nipp, R; Quinaglia, T; Tavares, E; Weekes, CD; Zafar, A, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 4.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 3.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 3.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "Capesitabine is a orally administered cytotoxic drug metabolized to 5-fluorouracil and is widely used in large intestine cancer and breast cancer therapy." | 3.75 | [Coronary artery disease attack caused by cytotoxic chemotherapy]. ( Eskola, M; Ilveskoski, E; Nikus, K; Tanner, M, 2009) |
| "Among the various pathophysiologic mechanisms proposed to explain the 5-fluorouracil cardiotoxicity, coronary vasospasm, occurring most frequently after the completion of the second or third dose of the cycle, has gained wide acceptance." | 3.72 | Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy. ( Giaccon, G; Mariani, G; Mastore, M, 2003) |
| "A case of 5-fluorouracil-induced cardiotoxicity, possibly due to coronary artery spasm, and mimicking acute anterolateral myocardial infarction is presented and discussed." | 3.71 | 5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. ( Campbell, NP; McGlinchey, PG; Webb, ST, 2001) |
| " Experimental studies revealed potential mechanisms of cardiotoxicity ranging from direct toxic effects on vascular endothelium involving endothelial NO synthase leading to coronary spasms and endothelium independent vasoconstriction via protein kinase C." | 2.43 | Cardiotoxicity of 5-fluorouracil. ( Alter, P; Herzum, M; Maisch, B; Schaefer, JR; Soufi, M, 2006) |
| " It has been shown experimentally that 5-FU has a direct toxic effect on the myocardium." | 2.38 | [Cardiotoxicity of 5-fluorouracil: coronary spasm? Apropos of 2 cases with normal coronarography]. ( Cristofini, P; Desnos, M; Funck, F; Guenot, O; Guerot, C; Hagege, A; Trotoux, J, 1989) |
| "Capecitabine has been shown to be much less cardiotoxic compared to 5-FU, with only a handful of cases reporting cardiotoxicity with capecitabine." | 1.43 | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016) |
| "Oral capecitabine is a prodrug of 5-fluorouracil that has been used into the management of multiple cancers because of the convenience of administration and efficacy at least comparable with 5-fluorouracil." | 1.40 | Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer. ( Cleator, S; Dzaye, O; Nihoyannopoulos, P, 2014) |
| "Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors." | 1.38 | Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012) |
| "Capecitabine is an orally available chemotherapeutic agent that is converted to 5-fluorouracil (5-FU) after absorbtion." | 1.38 | Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible. ( Celiker, E; Eren, M; Güvenç, TS; Ilhan, E; Ozcan, KS, 2012) |
| "The case of an 83-year-old man with colon cancer who developed chest pain during 5-FU infusion is presented." | 1.38 | A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. ( Cho, WH; Choi, SK; Kim, SB; Kim, SM; Kwak, CH; Lee, B; Sir, JJ, 2012) |
| " We stress the fact that while vasospasm is a well-recognized side-effect of this class of chemotherapeutic agent, broader cardiotoxicity is commonly seen and an increased awareness of the range of toxicity is necessary if repeat toxicity is to be avoided." | 1.36 | Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. ( Pavlakis, N; Stewart, T; Ward, M, 2010) |
| " The most (even if not fully) effective strategy was reducing capecitabine dosage together with nitrates, calcium-channel blockers and trimetazidine therapy." | 1.36 | Capecitabine cardiac toxicity presenting as effort angina: a case report. ( Crivellari, D; Lestuzzi, C; Meneguzzo, N; Rigo, F; Viel, E, 2010) |
| "Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil." | 1.35 | Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008) |
| "Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal." | 1.35 | Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008) |
| "Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU." | 1.34 | A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. ( Arbea, L; Coma-Canella, I; García-Foncillas, J; Martinez-Monge, R, 2007) |
| "Capecitabine is a new chemotherapeutic agent considered highly specific for sensitive tumour cells, which convert the drug to 5-fluorouracil." | 1.33 | Coronary artery spasm induced by capecitabine. ( Barone, C; Cassano, A; Crea, F; Lanza, GA; Pozzo, C; Sestito, A; Sgueglia, GA, 2006) |
| "Coronary artery vasospasms have been postulated to be involved in the pathogenesis of this rare but serious problem." | 1.30 | Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. ( Ferrari, S; Moroni, M; Nastasi, G; Porta, C, 1998) |
| "5-Fluorouracil is widely known to be toxic to the hematopoietic and gastrointestinal systems." | 1.29 | Clinical cardiotoxicity of 5-fluorouracil. ( Keefe, DL; Pierri, MK; Roistacher, N, 1993) |
| "5-fluorouracil is a drug that is widely used in cancerology." | 1.27 | [Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management]. ( Alexandre, JB; Escudier, B; Guyot, JM; Leclercq, B; Morin, P; Nitenberg, G, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (16.42) | 18.7374 |
| 1990's | 7 (10.45) | 18.2507 |
| 2000's | 27 (40.30) | 29.6817 |
| 2010's | 20 (29.85) | 24.3611 |
| 2020's | 2 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Zafar, A | 1 |
| Drobni, ZD | 1 |
| Lei, M | 1 |
| Gongora, CA | 1 |
| Quinaglia, T | 1 |
| Lou, UY | 1 |
| Mosarla, R | 1 |
| Murphy, SP | 1 |
| Jones-O'Connor, M | 1 |
| Mahmood, A | 1 |
| Hartmann, S | 1 |
| Gilman, HK | 1 |
| Weekes, CD | 1 |
| Nipp, R | 1 |
| Clark, JR | 2 |
| Clark, JW | 1 |
| Blaszkowsky, LS | 1 |
| Tavares, E | 1 |
| Neilan, TG | 1 |
| Boldig, K | 1 |
| Ganguly, A | 1 |
| Kadakia, M | 1 |
| Rohatgi, A | 1 |
| Kounis, NG | 2 |
| Koniari, I | 1 |
| Patsouras, N | 1 |
| Koutsogiannis, N | 1 |
| Velissaris, D | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Mukhopadhyay, A | 1 |
| Faridi, KF | 1 |
| Asnani, A | 1 |
| Osborn, EA | 1 |
| Yang, JX | 1 |
| Phillips, CT | 1 |
| York, M | 1 |
| Chakrabarti, S | 1 |
| Sara, J | 1 |
| Lobo, R | 1 |
| Eiring, R | 1 |
| Finnes, H | 1 |
| Mitchell, J | 1 |
| Hartgers, M | 1 |
| Okano, A | 1 |
| Halfdanarson, T | 1 |
| Grothey, A | 1 |
| Fradley, MG | 1 |
| Barrett, CD | 1 |
| Francis, SA | 1 |
| Klag, T | 1 |
| Cantara, G | 1 |
| Ong, P | 1 |
| Kaufmann, M | 1 |
| Sechtem, U | 1 |
| Athanasiadis, A | 1 |
| Dzaye, O | 1 |
| Cleator, S | 1 |
| Nihoyannopoulos, P | 1 |
| Vargo, CA | 1 |
| Blazer, M | 1 |
| Reardon, J | 1 |
| Gulati, M | 1 |
| Bekaii-Saab, T | 1 |
| Karakulak, UN | 1 |
| Aladağ, E | 1 |
| Maharjan, N | 1 |
| Övünç, K | 1 |
| Ben-Yakov, M | 1 |
| Mattu, A | 1 |
| Brady, WJ | 1 |
| Dubbs, SB | 1 |
| Goldsmith, YB | 1 |
| Roistacher, N | 2 |
| Baum, MS | 1 |
| Scott, PA | 1 |
| Ferchow, L | 1 |
| Hobson, A | 1 |
| Curzen, NP | 1 |
| Cerny, J | 1 |
| Hassan, A | 1 |
| Smith, C | 1 |
| Piperdi, B | 1 |
| Dalzell, JR | 1 |
| Samuel, LM | 1 |
| Ilveskoski, E | 1 |
| Nikus, K | 1 |
| Tanner, M | 1 |
| Eskola, M | 1 |
| Bathina, JD | 1 |
| Yusuf, SW | 1 |
| Farina, A | 1 |
| Malafronte, C | 1 |
| Valsecchi, MA | 1 |
| Achilli, F | 1 |
| Lestuzzi, C | 2 |
| Crivellari, D | 1 |
| Rigo, F | 1 |
| Viel, E | 2 |
| Meneguzzo, N | 2 |
| Stewart, T | 1 |
| Pavlakis, N | 1 |
| Ward, M | 1 |
| Atar, A | 1 |
| Korkmaz, ME | 1 |
| Ozin, B | 1 |
| Shah, NR | 1 |
| Shah, A | 1 |
| Rather, A | 1 |
| Karabay, CY | 1 |
| Gecmen, C | 1 |
| Aung, SM | 1 |
| Guler, A | 1 |
| Candan, O | 1 |
| Batgerel, U | 1 |
| Kalayci, A | 1 |
| Kirma, C | 1 |
| Tsigkas, GG | 1 |
| Almpanis, G | 1 |
| Mazarakis, A | 1 |
| Connolly, S | 1 |
| Scott, P | 1 |
| Cochrane, D | 1 |
| Harte, R | 1 |
| Ambrosy, AP | 1 |
| Kunz, PL | 1 |
| Fisher, GA | 1 |
| Witteles, RM | 1 |
| Güvenç, TS | 1 |
| Celiker, E | 1 |
| Ozcan, KS | 1 |
| Ilhan, E | 1 |
| Eren, M | 1 |
| Kim, SM | 1 |
| Kwak, CH | 1 |
| Lee, B | 1 |
| Kim, SB | 1 |
| Sir, JJ | 1 |
| Cho, WH | 1 |
| Choi, SK | 1 |
| Mariani, G | 1 |
| Giaccon, G | 1 |
| Mastore, M | 1 |
| Suresh, V | 1 |
| Khavandi, A | 1 |
| Hancock, H | 1 |
| Ceyhan, C | 1 |
| Meydan, N | 1 |
| Barutca, S | 1 |
| Tekten, T | 1 |
| Onbasili, AO | 1 |
| Ozturk, B | 1 |
| Unal, S | 1 |
| Bayrak, I | 1 |
| Karadag, O | 1 |
| Babaoglu, MO | 1 |
| Altundag, K | 1 |
| Elkiran, T | 1 |
| Yasar, U | 1 |
| Bozkurt, A | 1 |
| Pop, C | 1 |
| Nica, R | 1 |
| Vlaicu, R | 1 |
| Vinereanu, D | 1 |
| Alter, P | 2 |
| Herzum, M | 2 |
| Schaefer, JR | 2 |
| Maisch, B | 2 |
| Aksoy, S | 1 |
| Karaca, B | 1 |
| Dinçer, M | 1 |
| Yalçin, S | 1 |
| Duran, S | 1 |
| Bulur, S | 1 |
| Sozen, SB | 1 |
| Bilir, C | 1 |
| Uyan, C | 1 |
| Akdemir, R | 1 |
| Soufi, M | 1 |
| Sestito, A | 1 |
| Sgueglia, GA | 1 |
| Pozzo, C | 1 |
| Cassano, A | 1 |
| Barone, C | 1 |
| Crea, F | 1 |
| Lanza, GA | 1 |
| Spencker, S | 1 |
| Schmittel, A | 1 |
| Westermann, D | 1 |
| Marek, A | 1 |
| Schultheiss, HP | 1 |
| Witzenbichler, B | 1 |
| Arbea, L | 1 |
| Coma-Canella, I | 1 |
| Martinez-Monge, R | 1 |
| García-Foncillas, J | 1 |
| Coughlin, S | 1 |
| Das, S | 1 |
| Lee, J | 1 |
| Cooper, J | 1 |
| Papadopoulos, CA | 1 |
| Wilson, H | 1 |
| Shapira, I | 1 |
| Miller, HI | 1 |
| Braun, S | 1 |
| Laniado, S | 1 |
| Mizuno, Y | 1 |
| Hokamura, Y | 1 |
| Kimura, T | 1 |
| Kimura, Y | 1 |
| Kaikita, K | 1 |
| Yasue, H | 1 |
| Unverdorben, M | 1 |
| Birkenhake, S | 1 |
| Kunkel, B | 1 |
| Dunst, J | 1 |
| Keefe, DL | 1 |
| Pierri, MK | 1 |
| Porta, C | 1 |
| Moroni, M | 1 |
| Ferrari, S | 1 |
| Nastasi, G | 1 |
| Martínez Sellés, M | 1 |
| Pérez Castellano, N | 1 |
| Bueno Zamora, H | 1 |
| González Torrecilla, E | 1 |
| Abeytua Jiménez, M | 1 |
| Delcán Domínguez, JL | 1 |
| Heib, C | 1 |
| Schmidt, HJ | 1 |
| Heib, T | 1 |
| Lüer, B | 1 |
| Stasche, N | 1 |
| Schnetzler, B | 1 |
| Popova, N | 1 |
| Collao Lamb, C | 1 |
| Sappino, AP | 1 |
| Picano, E | 1 |
| Maseri, A | 1 |
| Lanza, G | 1 |
| Sucker, C | 1 |
| Scheffold, N | 1 |
| McGlinchey, PG | 1 |
| Webb, ST | 1 |
| Campbell, NP | 1 |
| Labianca, R | 1 |
| Luporini, G | 1 |
| Luwaert, RJ | 1 |
| Descamps, O | 1 |
| Majois, F | 1 |
| Chaudron, JM | 1 |
| Beauduin, M | 1 |
| Perreau, P | 1 |
| Jaulmes, H | 1 |
| Bokowy, C | 1 |
| Demaldent, JE | 1 |
| Mazoyer, G | 1 |
| Assouline, D | 1 |
| Fourchard, V | 1 |
| Kalb, JC | 1 |
| Cristofini, P | 1 |
| Desnos, M | 1 |
| Guenot, O | 1 |
| Funck, F | 1 |
| Hagege, A | 1 |
| Trotoux, J | 1 |
| Guerot, C | 1 |
| Fournier, C | 1 |
| Benahmed, M | 1 |
| Blondeau, M | 1 |
| Spain, M | 1 |
| McPherson, D | 1 |
| Escudier, B | 1 |
| Alexandre, JB | 1 |
| Leclercq, B | 1 |
| Morin, P | 1 |
| Guyot, JM | 1 |
| Nitenberg, G | 1 |
| Nakagawa, Y | 1 |
| Ogawa, N | 1 |
| Suzuki, H | 1 |
| Miki, H | 1 |
| Tominaga, M | 1 |
| Takahashi, M | 1 |
| Oleksowicz, L | 1 |
| Bruckner, HW | 1 |
| Burger, AJ | 1 |
| Mannino, S | 1 |
| Thyss, A | 1 |
| Falewee, MN | 1 |
| Leborgne, L | 1 |
| Viens, P | 1 |
| Schneider, M | 1 |
| Demard, F | 1 |
| Kleiman, NS | 1 |
| Lehane, DE | 1 |
| Geyer, CE | 1 |
| Pratt, CM | 1 |
| Young, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy[NCT04042298] | 106 participants (Anticipated) | Observational | 2019-06-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluorouracil and Coronary Artery Vasospasm
| Article | Year |
|---|---|
Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary | 2009 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr | 2009 |
Kounis syndrome is likely culprit of coronary vasospasm induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Coronary Vasospasm; Deoxycytidine; Fluorouracil; Humans; Male; Vent | 2012 |
Cardiotoxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Coronary Vasospasm; Endothelium, Vascular; Fluorouracil; H | 2006 |
[Cardiac toxicity of 5-fluorouracil. Reflections on a case].
Topics: Coronary Vasospasm; Fluorouracil; France; Humans; Male; Middle Aged | 1990 |
[Cardiotoxicity of 5-fluorouracil: coronary spasm? Apropos of 2 cases with normal coronarography].
Topics: Adult; Aged; Aged, 80 and over; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart | 1989 |
61 other studies available for fluorouracil and Coronary Artery Vasospasm
| Article | Year |
|---|---|
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
Topics: Calcium Channel Blockers; Coronary Vasospasm; Fluorouracil; Humans; Neoplasms; Nitrates; Retrospecti | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxici | 2022 |
Coronary vasospasm associated with 5-fluorouracil chemotherapy: Cardiac toxicity or cardiac hypersensitivity?
Topics: Acute Coronary Syndrome; Cardiotoxicity; Coronary Vasospasm; Drug Hypersensitivity; Fluorouracil; Hu | 2017 |
Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging.
Topics: Antimetabolites, Antineoplastic; Coronary Angiography; Coronary Vasospasm; Drug Substitution; Electr | 2018 |
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox | 2019 |
Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Coronary Angiography; Coronary Vasospasm; Defibrill | 2013 |
Epicardial coronary artery spasm as cause of capecitabine-induced tako tsubo cardiomyopathy.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Coronary Angiogr | 2014 |
Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.
Topics: Adult; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Thromb | 2014 |
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2016 |
Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Fluorouracil; Humans; | 2016 |
Prinzmetal angina (Coronary vasospasm) associated with 5-fluorouracil chemotherapy.
Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Coronary Ang | 2017 |
Capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; C | 2008 |
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Colorectal Neoplasms; Coronary Vaso | 2008 |
[Coronary artery disease attack caused by cytotoxic chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Vasospas | 2009 |
5-Fluorouracil-induced coronary vasospasm.
Topics: Aged; Antimetabolites, Antineoplastic; Cardiotoxins; Coronary Vasospasm; Female; Fluorouracil; Human | 2010 |
Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neop | 2009 |
Capecitabine cardiac toxicity presenting as effort angina: a case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cardiovascular Age | 2010 |
Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Capecitabine; Cardiotoxins; Cardiovascular Diseases; Coro | 2010 |
Two cases of coronary vasospasm induced by 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cecal Neoplasms; Coron | 2010 |
Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Defi | 2012 |
Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Coronary Vasospasm; Electrocardiograph | 2011 |
A case report of 5-fluorouracil-induced coronary artery vasospasm.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Coronary Vessels; Fluorou | 2010 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap | 2012 |
Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible.
Topics: Capecitabine; Coronary Thrombosis; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; | 2012 |
A case of severe coronary spasm associated with 5-fluorouracil chemotherapy.
Topics: Aged, 80 and over; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel | 2012 |
Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy.
Topics: Acute Disease; Adenocarcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary Angiography; Coro | 2003 |
5-flurouracil induced coronary artery vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Vasospasm; Electrocardiography; | 2004 |
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Colorectal Neoplas | 2004 |
5-Fluorouracil-induced coronary spasm: may inhibition of hyperpolarization factors produced by CYP2C enzymes be the cause?
Topics: Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Coronary Vasospasm; Cytochrome P-450 | 2004 |
Vasospastic angina caused by 5-fluorouracil. A case report.
Topics: Adenocarcinoma; Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary | 2003 |
Coronary artery spasm induced by 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coronary Angiograph | 2005 |
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Vasospasm | 2005 |
Images in emergency medicine: Acute severe coronary spasm associated with 5-fluorouracil chemotherapy.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Coronary Vasospasm; Electrocardiography; Emergencies | 2006 |
Coronary artery spasm induced by capecitabine.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, | 2006 |
[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; Dihydrouraci | 2007 |
Capecitabine induced vasospastic angina.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; F | 2008 |
Capecitabine-associated coronary vasospasm: a case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytid | 2008 |
[5-fluorouracil cardiotoxicity].
Topics: Adult; Aged; Coronary Vasospasm; Exercise Test; Female; Fluorouracil; Humans; Male; Middle Aged; Rad | 1982 |
A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction.
Topics: Aged; Breast Neoplasms; Chest Pain; Coronary Angiography; Coronary Vasospasm; Diagnosis, Differentia | 1995 |
[Extended reversible global left ventricular contraction dysfunction with symptomless coronary system as effect of cytostatic therapy with 5-fluorouracil].
Topics: Anus Neoplasms; Combined Modality Therapy; Coronary Angiography; Coronary Vasospasm; Diagnosis, Diff | 1994 |
Clinical cardiotoxicity of 5-fluorouracil.
Topics: Aged; Arrhythmias, Cardiac; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart Arr | 1993 |
Endothelin-1 and 5-fluorouracil-induced cardiotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Endothelin-1; Female; Fluorouracil; Heart | 1998 |
[Vasospasm following chemotherapy with 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Female; Fluorouracil; Humans | 2001 |
[Cardiotoxicity of 5-fluorouracil. Clinical relevance of palliative radiochemotherapy of malignant head-neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Coronary Vasospasm; Fluor | 2001 |
Coronary spasm induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2001 |
Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
Fluorouracil-induced coronary artery spasm.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Coronary Vasospasm; Exercise Test; Fluorouracil; H | 2001 |
[Coronary vasospasm during 5-fluorouracil chemotherapy].
Topics: Antimetabolites, Antineoplastic; Coronary Vasospasm; Diagnosis, Differential; Electrocardiography; F | 2001 |
5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Chest Pain; Coronary Angiography; Coronary Vasospasm; Diagnos | 2001 |
5-fluorouracil cardiotoxicity: the risk of rechallenge.
Topics: Angina Pectoris; Coronary Vasospasm; Fluorouracil; Humans; Myocardial Infarction; Recurrence | 1991 |
Coronary artery spasm induced by 5-fluorouracil.
Topics: Aged; Coronary Angiography; Coronary Vasospasm; Fluorouracil; Humans; Male | 1991 |
[Cardiotoxicity of 5 fluoro-uracil. Apropos of a case].
Topics: Coronary Vasospasm; Electrocardiography; Fluorouracil; Humans; Male; Middle Aged | 1989 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Aged; Arrhythmias, Cardiac; Coronary Vasospasm; Fluorouracil; Humans; Laryngeal Neoplasms; Male; Voc | 1989 |
5-Fluorouracil-induced angina.
Topics: Aged; Angina Pectoris; Coronary Vasospasm; Female; Fluorouracil; Humans; Liver Neoplasms; Platelet A | 1989 |
[Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management].
Topics: Coronary Disease; Coronary Vasospasm; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Age | 1986 |
[A case of variant angina induced by 5-fluorouracil and Tegafur].
Topics: Adenocarcinoma; Angina Pectoris, Variant; Coronary Vasospasm; Electrocardiography; Fluorouracil; Hum | 1988 |
Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers.
Topics: Aged; Angina Pectoris; Coronary Vasospasm; Female; Fluorouracil; Humans; Nifedipine | 1988 |
5-Fluorouracil-induced coronary vasospasm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Coronary Vasospas | 1987 |
[Cardiotoxicity of 5-fluorouracil. Spasm or direct myocardial toxicity?].
Topics: Aged; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart; Humans; Male; Middle Age | 1987 |
Prinzmetal's angina during 5-fluorouracil chemotherapy.
Topics: Angina Pectoris, Variant; Coronary Vasospasm; Electrocardiography; Fluorouracil; Humans; Injections, | 1987 |